DUBLIN, Oct. 26, 2016 /PRNewswire/ -- Allergan plc
(NYSE:AGN) today announced changes to leadership roles within its
board of directors. Effective today, Brenton L. Saunders has been elected Chairman of
the Allergan's Board of Directors replacing Paul Bisaro, who served as Executive Chairman
since July 1, 2014. Bisaro will
remain a member of the Allergan Board of Directors. In
addition to the role of Chairman, Saunders will retain his current
role as Chief Executive Officer and President. Also,
effective today, Christopher
Coughlin has been elected Lead Independent Director.
Logo -
http://photos.prnewswire.com/prnh/20150612/222796LOGO
"In 2013, Actavis was a leading global generics company when we
began our transformation into a branded leader by acquiring
Warner Chilcott. We followed
that by acquiring Forest Laboratories in 2014 and Allergan in
2015," said Paul
Bisaro. "With the sale of our Global Generics
business to Teva in August 2016 and
our Anda distribution business in October
2016, we have now completed the transformation to a global
branded Growth Pharma company with operations in nearly 100
countries and annual sales of approximately $15 billion. With this transformation
complete, this is the right time to transition leadership of the
Allergan Board of Directors to Brent, who has led the company so
ably since becoming CEO and President in July 2014." Saunders
has served as a member of Allergan's Board of Directors and as
Chief Executive Officer and President since July 2014. He was previously Chief Executive
Officer and President of Forest and a member of the Board of
Directors of Forest. He is currently a member of the Board of
Trustees of the University of
Pittsburgh, The Business Council and PhRMA.
"During his tenure with our company, Paul has provided
impressive leadership to Allergan and its Board of Directors. His
strategic vision led the way to our transformation. Paul's
wisdom, partnership and deep understanding of the biopharmaceutical
industry have been invaluable to me as we transformed Allergan into
a Growth Pharma leader, and I am happy that our Board will continue
to benefit from his expertise," said Brent
Saunders. "I would like to express my thanks to Paul, the
Nominating and Corporate Governance Committee and the full Allergan
Board of Directors for their continuing confidence and
support." Bisaro served as Executive Chairman of Allergan's
Board of Directors since July 2014.
He previously served as our President and Chief Executive Officer
and as Chairman of our Board of Directors beginning October 2013; prior to serving as Chairman he
served on the Board of Directors beginning September 2007. Bisaro currently serves on the
Boards of Directors of Zimmer Biomet Holdings, Inc. and Zoetis,
Inc. and on the Board of Visitors of the
Catholic University of America's Columbus School of Law.
"With his depth of experience in biopharmaceuticals, his
demonstrated skill in managing companies before, during and after
significant corporate transformations, and his extensive service on
public company boards, Chris
Coughlin is well suited to serve as Allergan's Lead
Independent Director," said Bisaro. "I would also like to
thank Cathy Klema, who has served as
our Lead Independent Director since 2014 and has been active in our
ongoing dialogue with shareholders." Klema remains a member
of the board. Coughlin is currently a member of Allergan's
Compensation Committee and the Nominating and Corporate Governance
Committee. In 2015, Coughlin was recognized by National
Association of Corporate Directors (NACD) as Director of the
Year. He joined the Allergan board in July 2014 after serving as a member of the Board
of Directors of Forest since 2011. Coughlin currently serves
as the Chairman of the Board of Dun & Bradstreet. He also
serves on the Board of Directors of Alexion Pharmaceuticals and
Hologic, Inc.
About Allergan plc
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland,
is a bold, global pharmaceutical company and a leader in a new
industry model – Growth Pharma. Allergan is focused on
developing, manufacturing and commercializing branded
pharmaceuticals, devices and biologic products for patients around
the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the
Company's R&D model, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. This approach has led to Allergan building one
of the broadest development pipelines in the pharmaceutical
industry with 70+ mid-to-late stage pipeline programs in
development.
Our Company's success is powered by our more than 16,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained
in this press release that refer to future events or other
non-historical facts are forward-looking statements that reflect
Allergan's current perspective of existing trends and information
as of the date of this release. Except as expressly required by
law, Allergan disclaims any intent or obligation to update these
forward-looking statements. Actual results may differ materially
from Allergan's current expectations depending upon a number of
factors affecting Allergan's business. These factors include, among
others, the difficulty of predicting the timing or outcome of FDA
approvals or actions, if any; the impact of competitive products
and pricing; market acceptance of and continued demand for
Allergan's products; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2015
and Quarterly Report on Form 10-Q for the quarter ended
June 30, 2016 (certain of such
periodic public filings having been filed under the "Actavis plc"
name). Except as expressly required by law, Allergan disclaims any
intent or obligation to update these forward-looking
statements.
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Lisa
DeFrancesco
|
|
(862)
261-7152
|
|
|
|
Media:
|
|
Mark
Marmur
|
|
(862)
261-7558
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-announces-changes-to-board-leadership-300351970.html
SOURCE Allergan plc